<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786161</url>
  </required_header>
  <id_info>
    <org_study_id>P 002617</org_study_id>
    <nct_id>NCT01786161</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients</brief_title>
  <acronym>CIV</acronym>
  <official_title>Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected
      methicillin-resistant Staphylococcus aureus (MRSA) infection. Therefore, it is vital to
      optimize the dosing of vancomycin for this critically ill population. The most efficacious
      method of administering vancomycin is debated in the literature. Since vancomycin is
      associated with slow bactericidal activity, it is important to closely monitor serum
      concentrations so as to achieve early target serum concentration, particularly when treating
      aggressive S. aureus infections. One study has shown that vancomycin infused continuously may
      enable faster and more consistent achievement of a therapeutic serum concentration when
      compared to intermittent infusion. A faster achievement in the goal serum vancomycin
      concentration would be a protective factor for intensive care unit mortality in patients with
      MRSA infection.

      Currently in the surgical ICU (SICU) of our institute, vancomycin is administered based on a
      vancomycin dosing nomogram. Less than fifty percent of the ICU patients following this
      nomogram achieved target vancomycin concentration of 15 after 24 hours. To better achieve
      target vancomycin concentration in 24 hours, we developed a new vancomycin dosing nomogram
      with a continuous infusion. The aim is to determine which of the two dosing nomogram is more
      efficient and safer for SICU patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early administration of effective antibiotics is the cornerstone of management in septic
      patients; however, altered pharmacokinetics in critically ill patients has lead to
      subtherapeutic antibiotic exposure with standard antibiotic dosing and administration. This
      is further evidenced by low therapeutic target achievement with our intermittent vancomycin
      dosing nomogram. Administering vancomycin by continuous infusions may lead to achieving a
      therapeutic concentration and AUC24 more quickly than the administration by intermittent
      infusions as well as provide a more consistent concentration throughout the dosing period.
      Therefore, a new vancomycin continuous infusion nomogram was developed to increase the
      achievement of a goal vancomycin concentration within 24 hours.

      We hypothesized that vancomycin administered as continuous infusion would achieve the
      therapeutic target sooner and more consistently than when administered as an intermittent
      infusion in critically ill surgical patients. The aims of this study were to determine the
      dosing differences between continuous (CIV) and intermittent (IIV) dosing in critically ill
      surgical intensive care unit (SICU) patients with preserved renal function and whether
      calculated Cockcroft-Gault Creatinine Clearance (CG CrCL) or measured creatinine clearance
      (CrCL) is a better predictor of vancomycin clearance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved the Target Vancomycin Concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Required to Reach the Therapeutic Levels</measure>
    <time_frame>as long as participants are receiving Vancomycin (mean (SD) 9 (3.8) days for continuous, 8.4 (4.1) days for intermittent)</time_frame>
    <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancomycin Concentration at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>MRSA - Methicillin Resistant Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Vancomycin with continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 hours continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin with intermittent dose interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infusion rate 1000mg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin continuous infusion</intervention_name>
    <description>Vancomycin 24 hour intravenous continuous infusion</description>
    <arm_group_label>Vancomycin with continuous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin intermittent dosing interval</intervention_name>
    <description>Vancomycin intravenous infusion at rate 1000mg/hr</description>
    <arm_group_label>Vancomycin with intermittent dose interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female &gt; 18 years of age admitted to Surgical ICUs with
             suspected infection

          -  Calculated creatinine clearance &gt; 60ml/min

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Allergic to vancomycin

          -  Calculated creatinine clearance &lt; 60ml/min

          -  Pregnant

          -  Vancomycin administration more than 8 hour and less than 24 hour prior to study
             enrollment

          -  Anticipated vancomycin treatment less than 2 days for surgical prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsin Lin, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>March 27, 2017</results_first_submitted>
  <results_first_submitted_qc>March 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hsin Jung Lin</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vancomycin With Continuous Infusion</title>
          <description>continuous 24 hours intravenous infusion
Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin With Intermittent Dose Interval</title>
          <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vancomycin Continous Infusion</title>
          <description>Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion infusion rate 1000mg/hr</description>
        </group>
        <group group_id="B2">
          <title>Intermittent Infusion</title>
          <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="14.1"/>
                    <measurement group_id="B2" value="53.7" spread="13.5"/>
                    <measurement group_id="B3" value="56.8" spread="14.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved the Target Vancomycin Concentration</title>
        <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin With Continuous Infusion</title>
            <description>continuous 24 hours intravenous infusion
Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin With Intermittent Dose Interval</title>
            <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved the Target Vancomycin Concentration</title>
          <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Required to Reach the Therapeutic Levels</title>
        <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
        <time_frame>as long as participants are receiving Vancomycin (mean (SD) 9 (3.8) days for continuous, 8.4 (4.1) days for intermittent)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin Continous Infusion</title>
            <description>continuous 24 hours intravenous infusion
Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Infusion</title>
            <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Time Required to Reach the Therapeutic Levels</title>
          <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="7"/>
                    <measurement group_id="O2" value="54.1" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vancomycin Concentration at 24 Hours</title>
        <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin Continous Infusion</title>
            <description>continuous 24 hours intravenous infusion
Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Infusion</title>
            <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
          </group>
        </group_list>
        <measure>
          <title>Vancomycin Concentration at 24 Hours</title>
          <description>The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="3.7"/>
                    <measurement group_id="O2" value="14.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected while subjects are receiving vancomycin therapy.</time_frame>
      <desc>Nephrotoxicity was defined as an increase in serum creatinine (SCr) by 0.5 mg/dL or at least a 50% increase from baseline over 2 consecutive SCr values.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vancomycin Continous Infusion</title>
          <description>continuous 24 hours intravenous infusion
Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion</description>
        </group>
        <group group_id="E2">
          <title>Intermittent Infusion</title>
          <description>infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotoxicity</sub_title>
                <description>Nephrotoxicity was defined as an increase in serum creatinine (SCr) by 0.5 mg/dL or at least a 50% increase from baseline over 2 consecutive SCr values.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hsin Lin</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177241314</phone>
      <email>hlin13@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

